A leading Pakistani pharmaceutical company, Macter International Limited, has introduced a new and advanced injectable medicine Tirza Term for the treatment of type 2 diabetes. The medicine is now officially available in the Pakistani market after receiving approval from the Drug Regulatory Authority of Pakistan (DRAP).
According to the company, Tirza Term is a modern injectable therapy specifically developed for patients suffering from type 2 diabetes mellitus. Its main purpose is to effectively and sustainably control blood sugar levels so that patients can lead a better daily life and reduce the risk of diabetes related complications.
Medical experts say that a key feature of this new medicine is that it is not limited to sugar control alone but also shows benefits in weight reduction. Many type 2 diabetes patients suffer from obesity or overweight, which makes sugar control more difficult. In this context, Tirza Term is being described as a medicine with dual benefits.
Officials of Macter International Limited stated that the medicine has been developed in line with modern scientific research and international medical standards. They claim that its use has not only improved blood sugar levels in patients but also had positive effects on overall metabolic health. The company believes this medicine could become a significant milestone in diabetes treatment in Pakistan.
Health experts note that diabetes has become a rapidly growing disease in Pakistan, affecting millions of people with type 2 diabetes. In such a situation, the availability of modern and effective medicines is urgently needed. The introduction of this new medicine will provide better treatment options for patients and may also help reduce the national burden of diabetes.
